Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Purpose Six years ago, in 2015, the Focused Ultrasound Foundation sponsored a workshop
to discuss, and subsequently transition the landscape, of focused ultrasound as a new …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR
agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL …

Background: Cabozantinib is approved, in various settings, for the treatment of renal cell
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …

Differentiating pseudoprogression from true tumor progression has become a significant
challenge in follow-up of diffuse infiltrating gliomas, particularly high grade, which leads to a …

Abstract Background Ofranergene obadenovec (VB-111) is an anticancer viral therapy that
demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma …

We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for
stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and …

Background VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene,
leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor …

BACKGROUND AND PURPOSE: Currently, contrast-enhancing margins on T1WI are used
to guide treatment of gliomas, yet tumor invasion beyond the contrast-enhancing region is a …